American Regent v. Dr. Reddy’s: Selenious Acid Patent Consolidated in 21 Days
American Regent, Inc. filed suit against Dr. Reddy’s Laboratories on December 13, 2024, asserting patent US12150957B2 over selenious acid pharmaceutical products. The action was consolidated into a broader multi-defendant litigation — In re Selenious Acid Litigation — within just 21 days, signalling a coordinated enforcement campaign against at least twelve generic challengers.
Mass enforcement action: ARI targets 12 generics over selenious acid patent
On December 13, 2024, American Regent, Inc. filed at least twelve parallel infringement actions in the District of New Jersey, each asserting US12150957B2 against a separate generic pharmaceutical manufacturer. The action against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. was docketed as Civil Action No. 2:24-cv-11114. The asserted patent covers selenious acid products — an essential trace element used in intravenous nutrition formulations — consistent with the Hatch-Waxman framework triggered by ANDA filings.
Within 21 days of filing, on January 3, 2025, the parties jointly stipulated to consolidate Case No. 2:24-cv-11114 along with eleven other parallel actions into the pre-existing In re Selenious Acid Litigation, Civil Action No. 2:24-cv-7791 (BRM)(CLW). Consolidation is a procedural mechanism that merges related cases before the same judge to promote efficiency; it does not resolve the merits. Dr. Reddy’s remains a named defendant in the consolidated proceeding and the infringement claims against it remain live.
The speed of consolidation — 21 days — suggests the court and parties anticipated significant overlap in claim construction, discovery, and scheduling across defendants. The breadth of the campaign (defendants include Accord, Cipla, Hikma, Sun Pharma, Zydus, and others) is consistent with a coordinated ANDA litigation strategy by the brand holder. What remains unknown from the public record is the precise ANDA filing dates, the specific claims asserted against Dr. Reddy’s, and whether any defendant has filed an early motion to dismiss or invalidity counterclaims.
Filing to Case Consolidated in 21 days
21 days to consolidation — unusually swift case management in pharma Hatch-Waxman litigation
Case consolidated: what the transfer to In re Selenious Acid Litigation means
Consolidation merges cases — it does not end them
Federal Rule of Civil Procedure 42(a) allows a court to consolidate actions sharing common questions of law or fact. Here, all twelve parallel actions were merged into 2:24-cv-7791. This is a procedural efficiency measure: filings, scheduling, and any future hearings proceed under one docket. The infringement claims against Dr. Reddy’s are fully preserved and actively pending in the consolidated matter.
Claims remain liveSame court, same judge — jurisdiction unchanged
Consolidation here does not involve a venue transfer to a different district. All actions remain before Judge Brian R. Martinotti in the District of New Jersey. The practical effect for Dr. Reddy’s is that its litigation strategy will be coordinated alongside — and potentially influenced by — the defences of eleven co-defendants. Claim construction rulings and discovery schedules will apply across all parties.
NJ District Court retainedConsolidated docket sets the stage for claim construction
Post-consolidation, the court typically issues a scheduling order covering discovery, claim construction briefing (Markman hearing), and trial. In Hatch-Waxman cases, a 30-month stay of FDA approval may be running concurrently, creating a defined litigation window. Dr. Reddy’s and co-defendants are expected to file answers and invalidity counterclaims under the consolidated caption 2:24-cv-7791.
Markman hearing ahead12 generic challengers signals contested patent validity
The simultaneous filing against twelve defendants strongly suggests each submitted an ANDA with a Paragraph IV certification challenging US12150957B2. The consolidated structure amplifies the commercial stakes: if any defendant succeeds in invalidating the patent, the benefit extends to all. American Regent faces a coordinated defence landscape, while each generic challenger may benefit from shared litigation costs and precedents set by the stronger-resourced co-defendants.
Shared invalidity incentiveFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical manufacturer and innovator — holder of US12150957B2 (selenious acid)Search in Eureka ↗ |
| Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Global generic pharmaceutical manufacturer; ANDA filer for selenious acid injectable productsSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects a stipulated agreement by all parties — not a contested judicial ruling on the merits. The language ‘good cause exists to consolidate’ is a procedural finding only. The infringement allegations against Dr. Reddy’s under US12150957B2 remain entirely unresolved. The order’s significance lies in its structural effect: all future substantive rulings, including claim construction and validity, will be made once and applied across twelve defendants simultaneously.
US12150957B2 — Selenious Acid Injectable Pharmaceutical Formulations
US12150957B2 (application number US18/672876) covers selenious acid products — pharmaceutical formulations of selenium used in intravenous nutrition, particularly in patients requiring parenteral trace element supplementation. The patent’s issuance under application US18/672876 suggests a relatively recent prosecution history. Selenious acid injectables are a niche but clinically critical product category, used in ICU and home parenteral nutrition settings where selenium deficiency poses serious health risks.
The strategic value of US12150957B2 lies in its ability to block or delay generic market entry for a product with established clinical demand and limited therapeutic substitution. The simultaneous assertion against twelve ANDA filers confirms that American Regent views this patent as the primary barrier to generic competition. For competitors in the injectable nutrition space, the patent’s claim scope — particularly formulation parameters, concentration ranges, and manufacturing methods — represents the key risk variable for freedom-to-operate analysis.
Should your injectable nutrition product be cleared against US12150957B2?
Any company developing, manufacturing, or planning to commercialise selenious acid injectable products — including parenteral nutrition trace element solutions — should conduct a freedom-to-operate analysis against US12150957B2. With twelve defendants already named, the patent is actively enforced and the claim scope is untested by any court ruling to date. Generic manufacturers, contract development organisations, and hospital formulary suppliers are all within the potential risk perimeter.
PatSnap Eureka’s FTO Search Agent can map the independent and dependent claims of US12150957B2 against your product specifications, identify prior art cited during prosecution that may define claim boundaries, and flag co-pending applications in the same family that could extend coverage. Given the consolidated litigation timeline, an early FTO assessment could inform both product design decisions and any potential inter partes review filing strategy before the Markman record is set.
Run a freedom-to-operate analysis on US12150957B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman Litigation: Selenious Acid & Injectable Nutrition Patents in NJ
Cases involving injectable pharmaceutical patents litigated under Hatch-Waxman in the District of New Jersey, including multi-defendant ANDA consolidations in the parenteral nutrition sector.
What this case signals for the injectable pharma IP landscape
A 12-defendant Hatch-Waxman wave in NJ raises the stakes for trace element injectable patent enforcement.
Multi-defendant ANDA suits compress timelines for brand holders
Filing against twelve generics on the same day and achieving consolidation within three weeks is consistent with a coordinated enforcement strategy designed to maximise the Hatch-Waxman 30-month stay and control claim construction centrally. Brand holders in the injectable nutrition space should monitor similar filing clusters as a signal of imminent generic entry.
Consolidation can dilute defendant leverage — or amplify it
When defendants with varied resources are consolidated, the litigation strategy is often shaped by the best-funded challenger. For Dr. Reddy’s, co-defendants like Sun Pharma and Hikma may drive validity arguments. Conversely, a weak settlement by one defendant can create precedent pressure. Monitoring individual defendant postures in 2:24-cv-7791 is essential.
American v Dr. — key questions answered
American Regent filed an infringement action on December 13, 2024 asserting patent US12150957B2 over selenious acid products. Within 21 days, on January 3, 2025, the case was consolidated by stipulation into In re Selenious Acid Litigation (2:24-cv-7791) in the District of New Jersey. The case was not dismissed; infringement claims remain active in the consolidated proceeding.
Consolidation under FRCP 42(a) merged Dr. Reddy’s case with eleven other parallel actions into a single docket (2:24-cv-7791). Dr. Reddy’s remains a named defendant. All future filings, scheduling orders, and substantive rulings — including claim construction — will occur in the consolidated matter. The infringement claims against Dr. Reddy’s are fully preserved.
US12150957B2 (application US18/672876) is held by American Regent and covers selenious acid injectable pharmaceutical products used in intravenous trace element nutrition. It is the central patent asserted against all twelve defendants in the In re Selenious Acid Litigation consolidated proceeding in the District of New Jersey.
At least twelve separate actions were filed by American Regent on December 13, 2024 and consolidated into 2:24-cv-7791. Named defendants include Dr. Reddy’s Laboratories, Accord Healthcare, Aspiro Pharma, Cipla, Gland Pharma, Hikma, RK Pharma, Somerset Therapeutics, Sun Pharmaceutical, Xiromed, and Zydus Pharmaceuticals, consistent with a coordinated Hatch-Waxman Paragraph IV enforcement campaign.
Yes. The consolidation order of January 3, 2025 is a procedural case management step. The consolidated action In re Selenious Acid Litigation (2:24-cv-7791) remains active in the District of New Jersey before Judge Brian R. Martinotti. No merits ruling, claim construction decision, or settlement has been publicly recorded in the consolidated matter as of the available data.
PatSnap Eureka searches patents and litigation data to answer instantly.